Literature DB >> 23811433

Generation of a large number of functional dendritic cells from human monocytes expanded by forced expression of cMYC plus BMI1.

Miwa Haruta1, Yusuke Tomita, Yuya Imamura, Keiko Matsumura, Tokunori Ikeda, Koutaro Takamatsu, Yasuharu Nishimura, Satoru Senju.   

Abstract

Anticancer vaccination therapies with monocyte-derived dendritic cells (DC) are widely conducted. A large number of primary monocytes (approximately 10(8) cells) are needed to generate the number of DC required to achieve an effect upon vaccination, and monocytes are usually purified from peripheral blood mononuclear cells obtained by apheresis procedure, which is somehow invasive for cancer patients. As a means to facilitate the generation of DC for therapeutic use, we herein report a method to amplify human monocytes. We found that lentivirus-mediated transduction of cMYC along with BMI1 induced proliferation of CD14(+) monocytes derived from 9 out of 12 blood donors, and we named the monocyte-derived proliferating cells CD14-ML. Their proliferation continued for 3-5 weeks in the presence of M-CSF and GM-CSF, resulting in 20-1000-fold amplification. Importantly, the expanded CD14-ML differentiated into fully functional DC (CD14-ML-DC) upon the addition of IL-4 to the culture. We successfully stimulated autologous CD8(+) T cells with CD14-ML-DC pulsed with cytomegalovirus peptide or MART-1 peptide to generate antigen-specific CTL lines. This is the first report describing the method for in vitro expansion of human peripheral blood monocytes.
Copyright © 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23811433     DOI: 10.1016/j.humimm.2013.05.017

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  11 in total

1.  Efficient Culture of Human Naive and Memory B Cells for Use as APCs.

Authors:  Kuei-Ying Su; Akiko Watanabe; Chen-Hao Yeh; Garnett Kelsoe; Masayuki Kuraoka
Journal:  J Immunol       Date:  2016-10-10       Impact factor: 5.422

2.  Generation of Large Numbers of Antigen-Expressing Human Dendritic Cells Using CD14-ML Technology.

Authors:  Yuya Imamura; Miwa Haruta; Yusuke Tomita; Keiko Matsumura; Tokunori Ikeda; Akira Yuno; Masatoshi Hirayama; Hideki Nakayama; Hiroshi Mizuta; Yasuharu Nishimura; Satoru Senju
Journal:  PLoS One       Date:  2016-04-06       Impact factor: 3.240

3.  An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs.

Authors:  Masatoshi Hirayama; Yusuke Tomita; Akira Yuno; Hirotake Tsukamoto; Satoru Senju; Yuya Imamura; Mohammad Abu Sayem; Atsushi Irie; Yoshihiro Yoshitake; Daiki Fukuma; Masanori Shinohara; Akinobu Hamada; Hirofumi Jono; Eiji Yuba; Kenji Kono; Koji Yoshida; Takuya Tsunoda; Hideki Nakayama; Yasuharu Nishimura
Journal:  Oncoimmunology       Date:  2016-01-04       Impact factor: 8.110

4.  Functional Analysis of Dendritic Cells Generated from T-iPSCs from CD4+ T Cell Clones of Sjögren's Syndrome.

Authors:  Mana Iizuka-Koga; Hiromitsu Asashima; Miki Ando; Chen-Yi Lai; Shinji Mochizuki; Mahito Nakanishi; Toshinobu Nishimura; Hiroto Tsuboi; Tomoya Hirota; Hiroyuki Takahashi; Isao Matsumoto; Makoto Otsu; Takayuki Sumida
Journal:  Stem Cell Reports       Date:  2017-05-09       Impact factor: 7.765

5.  Pluripotent Stem Cell Model of Nakajo-Nishimura Syndrome Untangles Proinflammatory Pathways Mediated by Oxidative Stress.

Authors:  Fumiko Honda-Ozaki; Madoka Terashima; Akira Niwa; Norikazu Saiki; Yuri Kawasaki; Haruna Ito; Akitsu Hotta; Ayako Nagahashi; Koichi Igura; Isao Asaka; Hongmei Lisa Li; Masakatsu Yanagimachi; Fukumi Furukawa; Nobuo Kanazawa; Tatsutoshi Nakahata; Megumu K Saito
Journal:  Stem Cell Reports       Date:  2018-05-03       Impact factor: 7.765

6.  Cancer therapy with major histocompatibility complex-deficient and interferon β-producing myeloid cells derived from allogeneic embryonic stem cells.

Authors:  Satoshi Umemoto; Miwa Haruta; Masataka Sakisaka; Tokunori Ikeda; Hirotake Tsukamoto; Yoshihiro Komohara; Motohiro Takeya; Yasuharu Nishimura; Satoru Senju
Journal:  Cancer Sci       Date:  2019-08-07       Impact factor: 6.716

7.  Pluripotent stem cell-based screening identifies CUDC-907 as an effective compound for restoring the in vitro phenotype of Nakajo-Nishimura syndrome.

Authors:  Naoya Kase; Madoka Terashima; Akira Ohta; Akira Niwa; Fumiko Honda-Ozaki; Yuri Kawasaki; Tatsutoshi Nakahata; Nobuo Kanazawa; Megumu K Saito
Journal:  Stem Cells Transl Med       Date:  2020-10-14       Impact factor: 6.940

8.  The potential of COVID-19 patients' sera to cause antibody-dependent enhancement of infection and IL-6 production.

Authors:  Jun Shimizu; Tadahiro Sasaki; Atsushi Yamanaka; Yoko Ichihara; Ritsuko Koketsu; Yoshihiro Samune; Pedro Cruz; Kei Sato; Naomi Tanga; Yuka Yoshimura; Ami Murakami; Misuzu Yamada; Kiyoe Itoi; Emi E Nakayama; Kazuo Miyazaki; Tatsuo Shioda
Journal:  Sci Rep       Date:  2021-12-09       Impact factor: 4.379

9.  Recapitulation of pro-inflammatory signature of monocytes with ACVR1A mutation using FOP patient-derived iPSCs.

Authors:  Hirotsugu Maekawa; Yonghui Jin; Megumi Nishio; Shunsuke Kawai; Sanae Nagata; Takeshi Kamakura; Hiroyuki Yoshitomi; Akira Niwa; Megumu K Saito; Shuichi Matsuda; Junya Toguchida
Journal:  Orphanet J Rare Dis       Date:  2022-09-21       Impact factor: 4.303

10.  Combinatorial sympathetic and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockades inhibit the murine melanoma growth by targeting infiltrating T cells.

Authors:  Bin Wang; Zhifang Xu; Nuchsupha Sunthamala; Tomonori Yaguchi; Jin Huang; Yutaka Kawakami; Yinan Gong; Huiling Tang; Shanshan Li; Yi Guo; Yongming Guo; Masahisa Jinushi
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.